Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin D Lu

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
JAAD International|November 24, 2021
Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort studyYuliya Lytvyn, Asfandyar Mufti, Hiba Zaaroura, et al.
Cell Reports|March 10, 2021
Phosphorylation state of the histone variant H2A.X controls human stem and progenitor cell fate decisionsLuca Orlando, Borko Tanasijevic, Mio Nakanishi, et al.
American Journal of Clinical Dermatology|March 31, 2021
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort StudyTiago Torres, Luis Puig, Ron Vender, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
JAAD International|November 24, 2021
Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort studyYuliya Lytvyn, Asfandyar Mufti, Hiba Zaaroura, et al.
Cell Reports|March 10, 2021
Phosphorylation state of the histone variant H2A.X controls human stem and progenitor cell fate decisionsLuca Orlando, Borko Tanasijevic, Mio Nakanishi, et al.
American Journal of Clinical Dermatology|March 31, 2021
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort StudyTiago Torres, Luis Puig, Ron Vender, et al.
Pageof 2